Charych Deborah H. 4

What Happened
Deborah H. Charych, a director of Skye Bioscience, was granted a derivative award covering 75,000 shares on March 31, 2026. The filing reports an acquisition at a reported price of $0.00 (derivative award/stock option), so no cash purchase was recorded on the Form 4. This is an award/grant (transaction code A), not a sale.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-02 (filed within the typical 2-business-day window).
• Transaction type/code: Grant/Award (A); reported price: $0.00.
• Number of derivative shares/options granted: 75,000.
• Vesting: Footnote states the stock option vests in equal monthly installments over the one-year period beginning March 31, 2026.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• This is a grant of a derivative security (stock option/award), not an open-market purchase or sale.

Context
A grant like this typically represents compensation or an incentive tied to continued service and future vesting; it does not reflect an immediate market purchase or sale of shares. For options, investors should note vesting schedules and potential exercise terms before treating the award as an indicator of insider conviction.